Sapienza Lucas Gomes, Flosi Adriana, Aiza Antonio, de Assis Pellizzon Antonio Cassio, Chojniak Rubens, Baiocchi Glauco
Department of Radiation Oncology, A.C. Camargo Cancer Center, São Paulo, 01509-010, Brazil.
Department of Radiation Oncology, Clínicas Oncológicas Integradas (COI-RJ), Rio de Janeiro, 22793-080, Brazil.
Sci Rep. 2016 Jun 14;6:28074. doi: 10.1038/srep28074.
There is no consensus on the use of computed tomography in vaginal cuff brachytherapy (VCB) planning. The purpose of this study was to prospectively determine the reproducibility of point bladder dose parameters (DICRU and maximum dose), compared with volumetric-based parameters. Twenty-two patients who were treated with high-dose-rate (HDR) VCB underwent simulation by computed tomography (CT-scan) with a Foley catheter at standard tension (position A) and extra tension (position B). CT-scan determined the bladder ICRU dose point in both positions and compared the displacement and recorded dose. Volumetric parameters (D0.1cc, D1.0cc, D2.0cc, D4.0cc and D50%) and point dose parameters were compared. The average spatial shift in ICRU dose point in the vertical, longitudinal and lateral directions was 2.91 mm (range: 0.10-9.00), 12.04 mm (range: 4.50-24.50) and 2.65 mm (range: 0.60-8.80), respectively. The DICRU ratio for positions A and B was 1.64 (p < 0.001). Moreover, a decrease in Dmax was observed (p = 0.016). Tension level of the urinary catheter did not affect the volumetric parameters. Our data suggest that point parameters (DICRU and Dmax) are not reproducible and are not the ideal choice for dose reporting.
在阴道袖状近距离放射治疗(VCB)计划中,对于计算机断层扫描的应用尚无共识。本研究的目的是前瞻性地确定点膀胱剂量参数(国际辐射单位与测量委员会(ICRU)剂量和最大剂量)与基于体积的参数相比的可重复性。22例接受高剂量率(HDR)VCB治疗的患者在标准张力(A位置)和额外张力(B位置)下通过带有Foley导管的计算机断层扫描(CT扫描)进行模拟。CT扫描确定了两个位置的膀胱ICRU剂量点,并比较了位移和记录的剂量。比较了体积参数(D0.1cc、D1.0cc、D2.0cc、D4.0cc和D50%)和点剂量参数。ICRU剂量点在垂直、纵向和横向方向上的平均空间位移分别为2.91毫米(范围:0.10 - 9.00)、12.04毫米(范围:4.50 - 24.50)和2.65毫米(范围:0.60 - 8.80)。A位置和B位置的ICRU剂量比为1.64(p < 0.001)。此外,观察到最大剂量(Dmax)降低(p = 0.016)。尿管的张力水平不影响体积参数。我们的数据表明,点参数(ICRU剂量和Dmax)不可重复,不是剂量报告的理想选择。